HCG 5000IU/amp 1 Ampulle by Knoll Pharmaceuticals

Usage

1. Confirm your cycle-end date and schedule the first HCG injection to fall within the final 7–14 days of anabolic steroid use, before initiating any SERM.
2. Remove the HCG 5000IU ampoule from refrigeration (2–8 °C) and allow it to reach room temperature for 5–10 minutes; inspect for visible particles or discolouration — do not use if either is present.
3. Reconstitute the lyophilised powder by slowly injecting 1–2 ml of bacteriostatic water for injection or sterile water for injection along the ampoule wall; swirl gently — never shake — until fully dissolved.
4. Draw the reconstituted solution into a sterile insulin syringe or 1 ml luer-lock syringe using a fresh 18–21G drawing needle, then switch to a 25–27G 5/8" injection needle for subcutaneous administration in the lower abdomen or upper thigh.
5. Administer the injection subcutaneously at the selected site, rotating injection sites between doses to minimise local tissue reaction; if splitting the 5,000 IU ampoule into two 2,500 IU doses, store the remaining reconstituted solution at 2–8 °C and use within 24 hours.
6. Log each injection date, dose, and site; begin your SERM-based PCT phase (tamoxifen or clomiphene) as planned and schedule a serum LH, FSH, and total testosterone panel at week 4 of PCT to objectively assess axis recovery.

Warnings

Frequently asked questions

When should I start using HCG in a post-cycle therapy protocol?

HCG should ideally be introduced in the final 1–2 weeks of an anabolic steroid cycle or in the 3–5 day bridge period before SERM-based PCT begins — not after PCT has already started. This timing targets the Leydig cells while gonadal suppression is still deep, priming testicular responsiveness so that tamoxifen or clomiphene can work more effectively on a partially reactivated axis.

How does HCG differ from SERMs like tamoxifen in post-cycle recovery?

HCG acts directly on Leydig cell LH receptors to stimulate intratesticular testosterone synthesis, bypassing the hypothalamic-pituitary axis entirely. SERMs such as tamoxifen work at the hypothalamic level by blocking oestrogen feedback, prompting the pituitary to release LH and FSH. HCG addresses gonadal atrophy first; SERMs then sustain pituitary-driven recovery — the two mechanisms are complementary rather than interchangeable.

How long does full testosterone axis recovery typically take after using HCG in PCT?

Full hypothalamic-pituitary-testicular axis recovery varies by cycle length and compound used, but clinical endocrinology data suggest that combining a short hCG phase with a 4–6 week SERM protocol normalises LH, FSH, and total testosterone in most healthy men within 8–16 weeks post-cycle. Longer or harsher cycles extend this timeline; monitoring serum testosterone and LH at 4-week intervals is the evidence-based approach to gauging recovery progress.

Is the single-ampoule format of HCG 5000IU better for sterility than multi-dose vials?

Yes — a single-use ampoule eliminates the repeated needle insertion and storage exposure that multi-dose vials require after first use. Once a multi-dose vial is opened, bacterial contamination risk rises with each subsequent draw. Knoll's single-ampoule presentation means the lyophilised powder is reconstituted immediately before injection and the entire 5,000 IU dose is used in one session, maintaining GMP-level sterility from manufacture through point of use.

How should HCG 5000IU ampoules be stored before reconstitution?

Lyophilised hCG ampoules must be stored refrigerated at 2–8 °C, away from light and moisture, to preserve peptide integrity. Do not freeze the ampoule. Once reconstituted with the supplied bacteriostatic water or sterile water for injection, the solution should be used within 30 minutes if plain sterile water is used, or within 24 hours if bacteriostatic water is used — always stored at 2–8 °C between preparation and injection. (2) angle_used

Manufacturer

Knoll Pharmaceuticals' entry into the injectable peptide hormone category reflects a quality infrastructure that differs structurally from the brand's oral-tablet segment: parenteral production demands an additional sterility dimension that lyophilised powder ampoule manufacturing must satisfy at every stage, from API acceptance through to final ampoule sealing and batch release. For the HCG 5000IU/amp line, that infrastructure centres on two analytically distinct checkpoints — HPLC quantification of hCG biological-unit content against a certified reference preparation, and LAL (Limulus Amebocyte Lysate) pyrogen testing to confirm endotoxin levels remain within injectable-product safety thresholds before any batch is cleared for distribution. The ampoule-format presentation itself is a manufacturing commitment: single-dose glass ampoules require hermetic sealing under controlled atmospheric conditions consistent with GMP parenteral guidelines, a process that locks in the sterility record established during production rather than relying on downstream cold-chain handling to compensate for any production shortfall. Within the bodybuilding supply market, Knoll Pharmaceuticals has maintained a position associated with per-lot release documentation — a traceability feature that allows batch-level quality verification rather than brand-level assumption, a distinction that matters particularly for injectable peptides where potency drift and endotoxin contamination carry direct physiological consequences.